These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25284038)

  • 1. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.
    Mirandola L; Yu Y; Cannon MJ; Jenkins MR; Rahman RL; Nguyen DD; Grizzi F; Cobos E; Figueroa JA; Chiriva-Internati M
    Gynecol Oncol; 2014 Dec; 135(3):573-9. PubMed ID: 25284038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?
    Mirandola L; Nguyen DD; Rahman RL; Grizzi F; Yuefei Y; Figueroa JA; Jenkins MR; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2014 Oct; 33(5):417-27. PubMed ID: 24801755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
    Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
    PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer.
    John CM; Leffler H; Kahl-Knutsson B; Svensson I; Jarvis GA
    Clin Cancer Res; 2003 Jun; 9(6):2374-83. PubMed ID: 12796408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer.
    Malone JM; Saed GM; Diamond MP; Sokol RJ; Munkarah AR
    Am J Obstet Gynecol; 2006 Apr; 194(4):1110-6; discussion 1116-8. PubMed ID: 16580304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periostin promotes ovarian cancer angiogenesis and metastasis.
    Zhu M; Fejzo MS; Anderson L; Dering J; Ginther C; Ramos L; Gasson JC; Karlan BY; Slamon DJ
    Gynecol Oncol; 2010 Nov; 119(2):337-44. PubMed ID: 20688362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin.
    Bieg D; Sypniewski D; Nowak E; Bednarek I
    Arch Gynecol Obstet; 2019 Apr; 299(4):1077-1087. PubMed ID: 30585294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
    Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells.
    Golubkov V; Garcia A; Markland FS
    Anticancer Res; 2005; 25(1A):249-53. PubMed ID: 15816545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro.
    O'Driscoll L; Linehan R; Liang YH; Joyce H; Oglesby I; Clynes M
    Anticancer Res; 2002; 22(6A):3117-25. PubMed ID: 12530054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.
    Deng W; Gu X; Lu Y; Gu C; Zheng Y; Zhang Z; Chen L; Yao Z; Li LY
    Angiogenesis; 2012 Mar; 15(1):71-85. PubMed ID: 22210436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
    Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis: a promising therapeutic target for ovarian cancer.
    Bamias A; Pignata S; Pujade-Lauraine E
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined effect of survivin-targeted shRNA and emodin on the proliferation and invasion of ovarian cancer cells.
    Xue H; Chen Y; Cai X; Zhao L; He A; Guo K; Zheng X
    Anticancer Drugs; 2013 Oct; 24(9):937-44. PubMed ID: 23921083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin inhibits the development and metastasis of ovarian cancer.
    Wu B; Li S; Sheng L; Zhu J; Gu L; Shen H; La D; Hambly BD; Bao S; Di W
    Oncol Rep; 2012 Sep; 28(3):903-8. PubMed ID: 22752027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
    Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
    Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3--a jack-of-all-trades in cancer.
    Newlaczyl AU; Yu LG
    Cancer Lett; 2011 Dec; 313(2):123-8. PubMed ID: 21974805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels.
    Yang F; Gou M; Deng H; Yi T; Zhong Q; Wei Y; Zhao X
    Oncol Rep; 2012 Aug; 28(2):668-76. PubMed ID: 22684947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression.
    Erices R; Cubillos S; Aravena R; Santoro F; Marquez M; Orellana R; Ramírez C; González P; Fuenzalida P; Bravo ML; Oliva B; Kato S; Ibañez C; Brañes J; Bravo E; Alonso C; García K; Arab C; Torres VA; Godoy AS; Pereira J; Bustos G; Cardenas JC; Cuello MA; Owen GI
    Oncotarget; 2017 Mar; 8(13):20865-20880. PubMed ID: 28209916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.